文献速递生殖医学

高窦卵泡计数女性中卵母细胞体外成熟与体外受精的有效性和安全性比较

The effectiveness and safety of in vitro maturation of oocytes versus in vitro fertilization in women with a high antral follicle count.
PubMed 文献 · Hum Reprod · 2019-01-01

该回顾性队列研究纳入919例高窦卵泡计数(AFC≥24)的不孕女性,其中608例接受卵母细胞体外成熟(IVM),311例接受体外受精(IVF)。IVM组首次移植后活产率为36.5%(222/608),IVF组为40.8%(127/311),调整OR为0.74(95%CI 0.42-1.30);一个完整周期的累积活产率IVM组为39.3%(239/608),IVF组为49.8%(155/311),调整OR为0.52(95%CI 0.30-0.89)。IVM组未发生卵巢过度刺激综合征(OHSS),IVF组发生11/311(3.5%)。

要点

  • 在高AFC不孕女性中,IVM组一个完整周期的累积活产率低于IVF组(39.3% vs 49.8%)。
  • IVM组未发生OHSS,IVF组OHSS发生率为3.5%(11/311)。
  • IVM组成熟卵母细胞、胚胎、优质胚胎和冷冻胚胎数量均显著低于IVF组。

核心结论

  • 在高AFC接受辅助生殖技术(ART)的女性中,与IVF相比,IVM是一种有效的替代方案,同时消除了OHSS风险。
  • 作者认为,在高AFC的不孕女性中,IVM是标准IVF的可行替代方案,可显著减少OHSS,并可能更患者友好且更具成本效益。

研究设计与样本

  • 回顾性队列研究,纳入919例女性,其中608例接受IVM,311例接受IVF。
  • 治疗于2015年7月至2017年12月在越南胡志明市My Duc医院IVFMD进行。
  • 研究对象为18-38岁、有ART指征且AFC≥24的不孕女性,根据患者或医生偏好接受IVM或IVF。

主要发现

  • IVM组(608个启动周期)有511次新鲜移植和167次冷冻移植;IVF组(311个启动周期)有209次新鲜移植和185次冷冻移植。
  • IVM组成熟卵母细胞、胚胎、优质胚胎和冷冻胚胎数量均显著低于IVF组。
  • 首次移植后活产率IVM组为222/608(36.5%),IVF组为127/311(40.8%),调整OR为0.74(95%CI 0.42-1.30)。
  • 一个完整周期累积活产率IVM组为239/608(39.3%),IVF组为155/311(49.8%),调整OR为0.52(95%CI 0.30-0.89)。
  • OHSS在IVM组未发生,IVF组为11/311(3.5%)。

关键数值与推荐

  • IVM周期:FSH 100 IU/天共3天,随后hCG 10000 IU。
  • IVF周期:促性腺激素释放激素拮抗剂方案,hCG 6500 IU触发。
  • 累积活产率定义为一个IVM/IVF周期所有新鲜和冷冻胚胎移植后的活产机会。

临床怎么用

  • 作者认为,在高AFC的不孕女性中,IVM是标准IVF的可行替代方案,可显著减少OHSS,并可能更患者友好且更具成本效益。

局限性

  • 研究受限于非随机设计。
  • 需要随机临床试验来精确比较IVM与IVF后的结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the effectiveness and safety of IVM compared with IVF for the treatment of women with high antral follicle count (AFC)? SUMMARY ANSWER: In women with high AFC undergoing assisted reproductive technique (ART), IVM is an effective alternative compared with IVF, while it eliminates the risk of ovarian hyperstimulation syndrome (OHSS). WHAT IS KNOWN ALREADY: IVM is postulated to be an alternative to conventional IVF to avoid OHSS. It has particular potential in women with high AFC who are known to be at increased risk of OHSS. To date, IVM and IVF have only been compared in small cohort studies. STUDY DESIGN, SIZE AND DURATION: We performed a retrospective cohort study including 919 women, of whom 608 underwent IVM and 311 IVF. The treatments were conducted at IVFMD, My Duc Hospital, Ho Chi Minh, Vietnam, from July 2015 to December 2017. PARTICIPANTS/MATERIALS, SETTING, METHODS: We studied infertile women aged 18-38 years with an indication for ART and with an AFC ≥24. Women received either IVM or IVF treatment depending on patient's or physician's preference. In IVM cycles, women received 3 days of FSH 100 IU/day followed by hCG 10 000 IU. In IVF cycles, women underwent a gonadotropin-releasing hormone antagonist protocol and were triggered with hCG 6500 IU. Outcome measures were live birth rate (LBR) after first embryo transfer and cumulative LBR after one complete cycle, defined as the chance of having live birth after all fresh and frozen transfers of embryos derived from one IVM/IVF cycle. We also report on clinical pregnancy, miscarriage, multiple pregnancy and OHSS. MAIN RESULTS AND THE ROLE OF CHANCE: Baseline characteristics including age and BMI were comparable between groups. In the IVM group (608 started cycles), there were 511 fresh and 167 frozen transfers. In the IVF group (311 started cycles), there were 209 fresh and 185 frozen transfers. The number of mature oocytes, embryos, good embryos and frozen embryos was significantly lower in the IVM compared with the IVF group. LBRs after the first transfer were 222/608 (36.5%) versus 127/311 (40.8%) (adjusted odds ratio [OR], 0.74; 95% confidence interval [CI], 0.42-1.30). Cumulative LBRs after one completed cycle were 239/608 (39.3%) versus 155/311 (49.8%) (adjusted OR, 0.52; 95% CI, 0.30-0.89). OHSS did not occur in the IVM group versus 11/311 (3.5%) in the IVF group. LIMITATIONS AND REASONS FOR CAUTION: Our study is limited by its non-randomized design. Randomized clinical trials are required to precisely compare the outcomes after IVM versus IVF. WIDER IMPLICATIONS OF THE FINDINGS: In infertile women with a high AFC, IVM is a feasible alternative to standard IVF that markedly reduces OHSS and is potentially more patient friendly and cost effective. STUDY FUNDING/COMPETING INTEREST(S): No external funding was sought to support this work. B.W.M. is supported by a National Health Medical Research Council Practitioner Fellowship (GNT1082548). B.W.M. reports consultancy for ObsEva, Merck and Guerbet. All other authors have no conflicts of interest. TRIAL REGISTRATION NUMBER: NA.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Ho VNA, Braam SC, Pham TD, et al. The effectiveness and safety of in vitro maturation of oocytes versus in vitro fertilization in women with a high antral follicle count. Hum Reprod. 2019. PMID: 31111879. doi:10.1093/humrep/dez060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。